Table of Contents
Cancer recurrence can begin months before it appears on a scan. And by the time imaging catches up, the disease may already be ahead.
Personalis, Inc. is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
Through its ultrasensitive MRD platform, NeXT Personal, Personalis is aiming to catch traces of cancer earlier using tumor-informed ctDNA testing.
The company’s traction suggests that strategy is gaining ground:
- 16,233 clinical tests in 2025, nearly 400% growth year over year
- Fresh Medicare coverage in breast and lung cancer
- Guidance for 43,000 to 45,000 clinical tests in 2026.
It is a sharp example of how precision oncology is shifting from one-time profiling toward longitudinal, real-time disease surveillance.
At JPM 2026, Onyx sat down with CEO Christopher Hall to find out more.
I hope you enjoy watching!
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW - a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea - AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
Yours sincerely,
Dr. Adil Ali
Comments